Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2010

01-06-2010 | ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgement

Published in: Cancer Immunology, Immunotherapy | Issue 6/2010

Login to get access

Excerpt

The aim of Cancer Immunology Immunotherapy is the communication of significant research documented by accurate, unambiguous data that are presented in an easily readable form. The style and quality of the journal depend to a great extent on the referees, who provide the authors with valuable criticism on the content and form of the papers submitted. These time-consuming services are provided without financial reward. The invaluable contribution of the following ad hoc reviewers in 2009 is herewith gratefully acknowledged: …
Metadata
Title
Acknowledgement
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0828-y

Other articles of this Issue 6/2010

Cancer Immunology, Immunotherapy 6/2010 Go to the issue

Original Article

Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment

Meeting Report

“Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany

Meeting Report

The second cellular therapy of cancer symposium, 27–29 March 2009, Milan, Italy

Original Article

Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity

Original Article

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

Original Article

Circulating tumour-derived microvesicles in plasma of gastric cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits